Kleinerüschkamp A G, Zacharowski K, Ettwein C, Müller M M, Geisen C, Weber C F, Meybohm P
Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland.
Dezernat 1, Finanz- und Rechnungswesen, Abteilung Operatives Controlling, Universitätsklinikum Frankfurt, Frankfurt am Main, Deutschland.
Anaesthesist. 2016 Jun;65(6):438-48. doi: 10.1007/s00101-016-0152-9. Epub 2016 May 9.
Patient blood management (PBM) is a multidisciplinary approach focusing on the diagnosis and treatment of preoperative anaemia, the minimisation of blood loss, and the optimisation of the patient-specific anaemia reserve to improve clinical outcomes. Economic aspects of PBM have not yet been sufficiently analysed.
The aim of this study is to analyse the costs associated with the clinical principles of PBM and the project costs associated with the implementation of a PBM program from an institutional perspective.
Patient-related costs of materials and services were analysed at the University Hospital Frankfurt for 2013. Personnel costs of all major processes were quantified based on the time required to perform each step. Furthermore, general project costs of the implementation phase were determined.
Direct costs of transfusing a single unit of red blood cells can be calculated to a minimum of €147.43. PBM-associated costs varied depending on individual patient requirements. The following costs per patient were calculated: diagnosis of preoperative anaemia €48.69-123.88; treatment of preoperative anaemia (including iron-deficiency anaemia and megaloblastic anaemia) €12.61-127.99; minimising perioperative blood loss (including point-of-care diagnostics, coagulation management and cell salvage) €3.39-1,901.81; and costs associated with the optimisation of the tolerance to anaemia (including patient monitoring and volume therapy) €28.62. General project costs associated with the implementation of PBM were €24,998.24.
PBM combines various alternatives to the transfusion of red blood cells and improves clinical outcome. Costs of PBM vary from institution to institution and depend on the extent to which different aspects of PBM have been implemented. The quantification of costs associated with PBM is essential in order to assess the economic impact of PBM, and thereby, to efficiently re-allocate health care resources. Costs were determined at a single university hospital. Thus, further analyses of both the costs of transfusion and the costs of PBM-principles will be necessary to evaluate the cost-effectiveness of PBM.
患者血液管理(PBM)是一种多学科方法,专注于术前贫血的诊断与治疗、失血的最小化以及患者特异性贫血储备的优化,以改善临床结局。PBM的经济方面尚未得到充分分析。
本研究旨在从机构角度分析与PBM临床原则相关的成本以及与实施PBM计划相关的项目成本。
对法兰克福大学医院2013年患者相关的材料和服务成本进行了分析。根据执行每个步骤所需的时间对所有主要流程的人员成本进行了量化。此外,还确定了实施阶段的一般项目成本。
输注单个单位红细胞的直接成本计算得出最低为147.43欧元。与PBM相关的成本因个体患者需求而异。计算得出每位患者的以下成本:术前贫血诊断48.69 - 123.88欧元;术前贫血治疗(包括缺铁性贫血和巨幼细胞贫血)12.61 - 127.99欧元;围手术期失血最小化(包括床旁诊断、凝血管理和细胞回收)3.39 - 1901.81欧元;以及与贫血耐受性优化相关的成本(包括患者监测和容量治疗)28.62欧元。与实施PBM相关的一般项目成本为24,998.24欧元。
PBM结合了多种替代红细胞输血的方法,并改善了临床结局。PBM的成本因机构而异,取决于PBM不同方面的实施程度。量化与PBM相关的成本对于评估PBM的经济影响至关重要,从而能够有效地重新分配医疗保健资源。成本是在一家大学医院确定的。因此,有必要进一步分析输血成本和PBM原则的成本,以评估PBM的成本效益。